The use of nonsteroidal anti-inflammatory drugs in chronic diseases of the musculoskeletal system. Etoricoxib – one drug, many possibilities Review article
Article Sidebar
Published:
Dec 31, 2023
Keywords:
nonsteroidal anti-inflammatory drugs, etoricoxib, osteoarthritis, rheumatoid arthritis, gout
Main Article Content
Abstract
Pain is the most important clinical symptom of chronic musculoskeletal diseases. It is fundamental for diagnosis and treatment to distinguish inflammatory from non-inflammatory pain. Nonsteroidal anti-inflammatory drugs, in particular cyclooxygenase 2 inhibitors (coxibs), including etoricoxib, play an important role in the pharmacotherapy of osteoarthritis and chronic arthritis. Etoricoxib is registered in the treatment of osteoarthritis, rheumatoid arthritis and gout. The mechanism of action, pharmacokinetics and a wide range of doses enable individualization of therapy and use in various groups of patients.
Article Details
How to Cite
Rupiński , R. (2023). The use of nonsteroidal anti-inflammatory drugs in chronic diseases of the musculoskeletal system. Etoricoxib – one drug, many possibilities. Medycyna Faktow (J EBM), 16(4(61), 416-421. https://doi.org/10.24292/01.MF.0423.20
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Malec-Milewska M, Woroń J. Kompendium leczenia bólu. Medical Education, Warszawa 2017.
2. Dobrogowski J, Wordliczek J, Woroń J. Leczenie bólu w praktyce lekarza POZ. Termedia, Poznań 2019.
3. Woroń J. Zastosowanie etorykoksybu w bólu zapalnym. Kiedy jest lekiem z wyboru? Lekarz POZ. 2023; 9(2): 99-104.
4. Mastalerz-Migas A, Kwiatkowska B, Majdan M et al. Etricoxib – the possibility of its use in the practice of the general practitioner. Lekarz POZ. 2017; 3(5): 351-7.
5. da Costa BR, Reichenbach S, Keller N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016; 387(10033): 2093-105.
6. ChPL. Etorykoksyb.
7. Moss P, Benson HAE, Will R et al. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017; 25 (11): 1781-91.
8. Nakata K, Hanai T, Take Y et al. Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2018; 26(10): 1263-73.
9. Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol. 2006; 20: 3-25.
10. Bruy O, Honvo G, Veronesec N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49(3): 337-50.
11. Puopolo A, Boice JA, Fidelholtz JL et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage. 2007; 15: 1348-56.
12. Laine L, Curtis SP, Cryer B et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007; 369: 465-73.
13. Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368: 1771-81.
14. Bickham K, Kivitz AJ, Mehta A et al. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskletal Disorders. 2016; 17: 331-42.
15. Zimmermann-Górska I. Dna moczanowa. Interna Szczeklika.
16. Croom KF, Siddiqui MA. Etoricoxib. A review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Cochrane Database Syst Rev. 2014; 9: CD010120.
17. Zhang S, Zhang Y, Liu P et al. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol. 2016; 35: 151-8.
2. Dobrogowski J, Wordliczek J, Woroń J. Leczenie bólu w praktyce lekarza POZ. Termedia, Poznań 2019.
3. Woroń J. Zastosowanie etorykoksybu w bólu zapalnym. Kiedy jest lekiem z wyboru? Lekarz POZ. 2023; 9(2): 99-104.
4. Mastalerz-Migas A, Kwiatkowska B, Majdan M et al. Etricoxib – the possibility of its use in the practice of the general practitioner. Lekarz POZ. 2017; 3(5): 351-7.
5. da Costa BR, Reichenbach S, Keller N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016; 387(10033): 2093-105.
6. ChPL. Etorykoksyb.
7. Moss P, Benson HAE, Will R et al. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017; 25 (11): 1781-91.
8. Nakata K, Hanai T, Take Y et al. Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2018; 26(10): 1263-73.
9. Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol. 2006; 20: 3-25.
10. Bruy O, Honvo G, Veronesec N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49(3): 337-50.
11. Puopolo A, Boice JA, Fidelholtz JL et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage. 2007; 15: 1348-56.
12. Laine L, Curtis SP, Cryer B et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007; 369: 465-73.
13. Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368: 1771-81.
14. Bickham K, Kivitz AJ, Mehta A et al. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskletal Disorders. 2016; 17: 331-42.
15. Zimmermann-Górska I. Dna moczanowa. Interna Szczeklika.
16. Croom KF, Siddiqui MA. Etoricoxib. A review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Cochrane Database Syst Rev. 2014; 9: CD010120.
17. Zhang S, Zhang Y, Liu P et al. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol. 2016; 35: 151-8.